GhayasC.IssaMD

PubMed

• 107 citations
  Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: A single-institution experience
  Kamal Chamoun, Hagop M. Kantarjian, Rami Atallah, Graciela M. Nogueras González, Ghayas C. Issa
  Journal of Hematology & Oncology. 2019-01-03
• 26 citations
  Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
  Nicholas J. Short, Keyur P. Patel, Maher Albitar, Miguel Franquiz, Rajyalakshmi Luthra
  Blood Advances. 2020-04-28
• 81 citations
  Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
  Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval Daver
  Haematologica. 2020-06-04

Abstracts/Posters

• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute ...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018